A handful of Chinese biotechnology companies are expected to bring medications to consumers in Europe and the US under their own brand names within the next 10 to 15 years, according to policy and industry analysts.
Amid China’s early-stage drug outlicensing boom, discussions have arisen among investor and analyst circles as to when – and which – Chinese biotechnology companies will start selling their own drugs internationally.
Outlicensing agreements typically refer to a company granting…
